/IMRX
IMRX Stock - Immuneering Corporation
Healthcare|BiotechnologyNASDAQ
$5.65-0.35%
$0.02 (-0.35%) • Dec 19
80
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.60
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+271.7%upside
Target: $21.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for IMRX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$5.59 – $5.71
TARGET (TP)$21.00
STOP LOSS$5.20
RISK/REWARD1:34.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.46
52W High$10.08
52W Low$1.10
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | $316,952 | $2.08M | $2.31M |
| Gross Profit | N/A | N/A | $158,830 | $926,888 | $1.03M |
| Gross Margin | N/A | N/A | 50.1% | 44.6% | 44.6% |
| Operating Income | $-64,071,401 | $-58,412,887 | $-51,744,868 | $-33,886,069 | $-17,082,554 |
| Net Income | $-61,036,608 | $-53,471,622 | $-50,513,568 | $-33,535,748 | $-17,039,898 |
| Net Margin | N/A | N/A | -15937.3% | -1612.3% | -737.2% |
| EPS | $-2.04 | $-1.88 | $-1.87 | $-1.27 | $-1.26 |
Company Overview
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
67%
Hold / Neutral
3
33%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
6 Bullish3 Neutral/Bearish
Price Targets
$15
Average Target
↑ 156.6% Upside
Now
$3
Low
$15
Average
$25
High
Based on 10 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 31st 2025 | Leerink Partners | Initiation | Outperform | $15 |
| December 13th 2024 | Morgan Stanley | Downgrade | Underweight | - |
| March 15th 2024 | Needham | Reiterated | Buy | $15← $20 |
| March 15th 2024 | TD Cowen | Downgrade | Market Perform | - |
| March 15th 2024 | Jefferies | Downgrade | Hold | $3← $16 |
| December 1st 2023 | Needham | Initiation | Buy | $20 |
| June 26th 2023 | Oppenheimer | Resumed | Outperform | $25 |
| April 19th 2023 | Morgan Stanley | Upgrade | Equal Weight | $14← $5 |
| April 19th 2023 | Mizuho | Upgrade | Buy | $20← $10 |
| March 30th 2023 | Mizuho | Initiation | Neutral | $10 |
| February 3rd 2023 | Morgan Stanley | Downgrade | Underweight | $5← $12 |
| July 8th 2022 | Chardan Capital Markets | Initiation | Buy | $18 |
Earnings History & Surprises
IMRXBeat Rate
44%
Last 18 quarters
Avg Surprise
+1.0%
EPS vs Estimate
Beats / Misses
8/9
1 met exactly
Latest EPS
$-0.38
Q4 2025
EPS Surprise History
Q1 24
-8.3%
$-0.52vs$-0.48
Q2 24
-8.9%
$-0.49vs$-0.45
Q3 24
+7.8%
$-0.47vs$-0.51
Q4 24
+9.3%
$-0.49vs$-0.54
Q1 25
-38.1%
$-0.58vs$-0.42
Q2 25
-2.4%
$-0.42vs$-0.41
Q3 25
0.0%
$-0.40vs$-0.40
Q4 25
-2.7%
$-0.38vs$-0.37
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 19, 2026 | $-0.31 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.37 | $-0.38 | -2.7% | ✗ MISS |
Q3 2025 | Aug 13, 2025 | $-0.40 | $-0.40 | 0.0% | = MET |
Q2 2025 | May 5, 2025 | $-0.41 | $-0.42 | -2.4% | ✗ MISS |
Q1 2025 | Mar 20, 2025 | $-0.42 | $-0.58 | -38.1% | ✗ MISS |
Q4 2024 | Nov 13, 2024 | $-0.54 | $-0.49 | +9.3% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $-0.51 | $-0.47 | +7.8% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $-0.45 | $-0.49 | -8.9% | ✗ MISS |
Q1 2024 | Mar 1, 2024 | $-0.48 | $-0.52 | -8.3% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.51 | $-0.43 | +15.7% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-0.54 | $-0.43 | +20.4% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $-0.54 | $-0.51 | +5.6% | ✓ BEAT |
Q1 2023 | Mar 6, 2023 | $-0.58 | $-0.50 | +13.8% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-0.48 | $-0.49 | -2.1% | ✗ MISS |
Q3 2022 | Aug 10, 2022 | $-0.52 | $-0.44 | +15.4% | ✓ BEAT |
Q2 2022 | May 10, 2022 | $-0.44 | $-0.49 | -11.4% | ✗ MISS |
Q1 2022 | Mar 10, 2022 | $-0.39 | $-0.42 | -7.7% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-0.61 | $-0.47 | +23.0% | ✓ BEAT |
Q3 2021 | Sep 9, 2021 | $-1.44 | $-1.61 | -11.8% | ✗ MISS |
Q3 2021 | Jul 30, 2021 | — | $-0.46 | — | — |
Latest News
Immuneering On Track To First Patient Dosing For Phase 3 Atebimetinib Trial For First-Line Metastatic Pancreatic Cancer Patients; Completed End-Of-Phase 2 Interaction With FDA And Received Scientific Advice From EMA
📈 PositiveBenzinga•Dec 17, 2025, 09:07 PM
Immuneering To Be Added To Nasdaq Biotechnology Index, Effective December 22
📈 PositiveBenzinga•Dec 16, 2025, 01:03 PM
Chardan Capital Maintains Buy on Immuneering, Maintains $20 Price Target
📈 PositiveBenzinga•Nov 13, 2025, 01:51 PM
Immuneering Q3 EPS $(0.38) Beats $(0.39) Estimate
📈 PositiveBenzinga•Nov 12, 2025, 09:06 PM
Leerink Partners Initiates Coverage On Immuneering with Outperform Rating, Announces Price Target of $15
📈 PositiveBenzinga•Oct 31, 2025, 11:02 AM
HC Wainwright & Co. Reiterates Buy on Immuneering, Maintains $11 Price Target
📈 PositiveBenzinga•Sep 30, 2025, 11:43 AM
Immuneering To Host Call On September 29, 2025 At 8:30 am ET To Discuss Updated Survival And Safety Data For Atebimetinib + mGnP In First-Line Pancreatic Cancer
➖ NeutralBenzinga•Sep 26, 2025, 08:01 PM
Chardan Capital Maintains Buy on Immuneering, Raises Price Target to $20
📈 PositiveBenzinga•Sep 26, 2025, 11:36 AM
Immuneering shares are trading lower after the company announced a $175 million underwritten public offering of Class A common stock and a concurrent $25 million private placement to Sanofi.
📉 NegativeBenzinga•Sep 25, 2025, 04:53 PM•Also:
Oppenheimer Maintains Outperform on Immuneering, Raises Price Target to $30
📈 PositiveBenzinga•Sep 25, 2025, 01:57 PM
Immuneering Prices $175M Underwritten Public Offering Of 18,959,914 Class A Common Stock; Concurrent $25M Private Placement To Sanofi
➖ NeutralBenzinga•Sep 25, 2025, 06:17 AM•Also:
Immuneering surges 40% on mid-stage atebimetinib data in pancreatic cancer
📈 PositiveSeeking Alpha•Sep 24, 2025, 08:58 PM
Immuneering announces public offering, $25M private placement with Sanofi; shares down 55%
📉 NegativeSeeking Alpha•Sep 24, 2025, 08:28 PM•Also:
Immuneering Announces Public Offering And $25M Private Placement With Sanofi
📈 PositiveBenzinga•Sep 24, 2025, 08:11 PM•Also:
Immuneering Announces Updated Survival And Safety Data From Its Ongoing Phase 2a Trial Of Atebimetinib In Combination With Modified Gemcitabine/Nab-Paclitaxel In First-line Pancreatic Cancer Patients, With 9 Months Median Follow Up; 86% Overall Survival Observed At 9 Months; Co. Expects Regulatory Feedback On Pivotal Trial Plans In Q4 2025 And, Subject To That Feedback, Expects To Initiate Pivotal Trial By The End Of 2025 And Begin Dosing Patients By Mid-2026
📈 PositiveBenzinga•Sep 24, 2025, 08:04 PM
Immuneering shares are trading higher after the company reported 86% overall survival at 9 months in first-line pancreatic cancer patients treated with Atebimetinib plus mGnP.
📈 PositiveBenzinga•Sep 24, 2025, 08:03 PM
Immuneering Names Thomas Schall Chairman Of The Board, Replaces Ben Zeskind In Leadership Transition
➖ NeutralBenzinga•Sep 16, 2025, 11:12 AM
Needham Maintains Buy on Immuneering, Raises Price Target to $11
📈 PositiveBenzinga•Sep 15, 2025, 10:48 AM
Biotech Firm Immuneering Plans Key Cancer Data Presentations At Upcoming Boston Summits
📈 PositiveBenzinga•Sep 10, 2025, 11:12 AM
Needham Reiterates Buy on Immuneering, Maintains $8 Price Target
📈 PositiveBenzinga•Aug 26, 2025, 10:25 AM
Frequently Asked Questions about IMRX
What is IMRX's current stock price?
Immuneering Corporation (IMRX) is currently trading at $5.65 per share. The stock has moved -0.35% today.
What is the analyst price target for IMRX?
The average analyst price target for IMRX is $21.00, based on 1 analyst.
What sector is Immuneering Corporation in?
Immuneering Corporation operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is IMRX's market cap?
Immuneering Corporation has a market capitalization of $0.21 billion, making it a small-cap company.
Does IMRX pay dividends?
No, Immuneering Corporation does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARCT
Arcturus Therapeutics Holdings Inc.
$6.53
Mkt Cap: $0.2B
ASMB
Assembly Biosciences, Inc.
$35.26
Mkt Cap: $0.3B
ENTA
Enanta Pharmaceuticals, Inc.
$15.39
Mkt Cap: $0.3B
FHTX
Foghorn Therapeutics Inc.
$5.24
Mkt Cap: $0.3B
HUMA
Humacyte, Inc.
$1.11
Mkt Cap: $0.2B
NAUT
Nautilus Biotechnology, Inc.
$1.94
Mkt Cap: $0.2B
PYXS
Pyxis Oncology, Inc.
$1.27
Mkt Cap: $0.1B
TNYA
Tenaya Therapeutics, Inc.
$0.70
Mkt Cap: $0.1B
TRDA
Entrada Therapeutics, Inc.
$10.98
Mkt Cap: $0.4B
ZURA
Zura Bio Limited
$4.27
Mkt Cap: $0.3B
Explore stocks similar to IMRX for comparison